First Zantac cancer case dropped before trial, without settlement
The first lawsuit claiming that gastrointestinal drug Zantac causes cancer has been voluntarily dismissed a week before it was due to come to trial, in […]
The first lawsuit claiming that gastrointestinal drug Zantac causes cancer has been voluntarily dismissed a week before it was due to come to trial, in […]
GSK, its consumer health spin-off Haleon and Sanofi could be on the hook for billions of dollars in potential damages over Zantac, a gastrointestinal drug […]
A panel discussion from a recent Microsoft summit offered insights on how tech companies are closely collaborating with the pharma industry as they seek to […]
Beijing biotech Sironax has closed a whopping $200 million second-round financing that shows investors still have a desire to back companies working on RIPK1 inhibitors […]
In its first set of financial figures since spinning off its consumer health division, GSK has reported a 19% increase in revenues, driven by burgeoning […]
GSK’s former head of vaccines R&D – Dr Emmanuel Hanon – is heading up a new biotech called Vicebio that will go up against his […]
Consumer goods spin-off makes few waves in biggest European listing for more than a decade It’s early days for Haleon, GlaxoSmithKline’s consumer goods spin-off, but […]
GSK’s consumer health spinout Haleon started trading on the London Stock Exchange this morning, making its debut with a price of 330 pence and a […]
Consumer health company’s shares open at 330p, giving it a market value of about £31bn GSK’s consumer spin-off Haleon, home to brands from Sensodyne toothpaste […]
Teva has asked the Supreme Court to look at a judgment in a $235 million patent dispute with GSK that it claims could undermine the […]
UK pharmaceutical to spin off brands such as Sensodyne, Voltaren and Panadol into Haleon in largest listing since 2011 Investors in the British pharmaceuticals giant […]
GSK’s recently-unveiled plan to develop a bioscience cluster close to its main R&D site in Stevenage, UK, has moved closer to fruition, now that the […]
Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are also fighting a patent infringement battle in […]
Barry Mulchrone, Senior Director& Head of Pharmacovigilance Oversight and Analytics, IQVIA Annette Williams, VP & Global Head, Lifecycle Safety, IQVIA Monitoring the safe and effective […]
Future booster campaigns against COVID-19 should include vaccines with a component targeting the Omicron variant of SARS-CoV-2, according to the FDA’s Vaccines and Related Biological […]
An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV) in a mid-stage trial, setting up a phase 3 […]
GSK will invest around £1 billion ($1.2 billion) over a 10-year period to speed up R&D on infectious diseases that mainly impact lower-income countries. The […]
With vaccine hesitancy leading to a rise in measles cases, the FDA’s approval of GlaxoSmithKline’s venerable vaccine Priorix for sale in the US looks timely. […]
GlaxoSmithKline is due to complete the split from its consumer health decision – now renamed Haleon – next month, with a listing for the new […]
GlaxoSmithKline has agreed a $3.3 billion takeover of US biotech Affinivax, buying a pneumococcal vaccine candidate that is aiming to break into a market that […]
GlaxoSmithKline is reportedly close to finding a development partner for a major new investment project in the UK that will see a new bioscience cluster […]
Industrial action at several GlaxoSmithKline manufacturing plants in the UK has been called off, after an improved pay deal was accepted by the Unite union. […]
iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a […]
GlaxoSmithKline blames shortage of key ingredient for lack of Piriton and Piriteze tablets Big high street pharmacy chains including Boots and Superdrug have run out […]
A scientist working in Switzerland has become the fifth person to be convicted of attempting to steal trade secrets from pharmaceutical group GlaxoSmithKline in a […]
GlaxoSmithKline has made a promising start to 2022 with a 32% rise in group sales, albeit measured against a downbeat first-quarter result in 2021. Vir […]
Workers at a number of GlaxoSmithKline manufacturing plants in the UK have voted to take industrial action over what the Unite union has described as […]
GlaxoSmithKline says the FDA has started its review of daprodustat for anaemia associated with chronic kidney disease (CKD), as it strives to succeed where two […]
GlaxoSmithKline is further building out its cancer drug portfolio by acquiring Sierra Oncology, a biotech whose FDA-ready myelofibrosis drug has clinical data showing advantages over […]
GlaxoSmithKline’s £1.5bn Sierra Oncology deal comes after pressure to boost its pipeline from Elliott The UK drug company GlaxoSmithKline has agreed a £1.5bn deal to […]
GlaxoSmithKline has agreed a deal to buy Sierra Oncology and its lead drug momelotinib for anaemia associated with the blood cancer myelofibrosis, sending the US […]
What You Should Know: – PathAI and GSK announced a multi-year strategic artificial intelligence (AI) partnership today with a focus on accelerating research and- building drug development programs […]
GlaxoSmithKline and Vir’s Xevudy has become the latest COVID-19 antibody therapy to have its use restricted by the FDA as a result of waning activity […]
The FDA has given ViiV healthcare and Johnson & Johnson a boost in the market for long-acting injectable HIV drugs, approving a new regimen for […]
GlaxoSmithKline has thrown its financial and drug development weight behind LifeMine Therapeutics, a US startup that aims to find new therapeutics from fungi – widely […]
LifeMine Therapeutics, a company that analyzes fungal genomes to find molecules that have potential as new medicines, has raised $175 million in financing. Among the […]
Bavarian Nordic has licensed rights to its respiratory syncytial virus (RSV) vaccine in China and certain other Asian markets to Shanghai’s Nuance Pharma in a […]
Merck & Co’s KEYNOTE-158 trial of Keytruda has underpinned another FDA approval, this time for the PD-1 inhibitor as a single-agent therapy as a therapy […]
With the healthcare sector accounting for around 4% of global emissions – about the same as a small country – only an ecosystem-wide effort will […]
AstraZeneca (AZ), GlaxoSmithKline (GSK), Sanofi, Allergan and Britannia Pharma have been reprimanded for running advertisements that breached the Association of British Pharmaceutical Industry (APBI) code […]
Pharma firm joins AstraZeneca and Pfizer in saying it will not enrol new patients into studies Russia-Ukraine war: latest updates What we know on day […]
AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal […]
Pfizer has been awarded breakthrough status from the FDA for its respiratory syncytial virus (RSV) vaccine in pregnant women, putting the company in pole position […]
Oil is always a political business, and there’s no point pretending otherwise First BP, now Shell. The rush to disinvest from Russia is impressively quick […]
Expected to be the biggest London listing in a decade, the Haleon demerger is scheduled for July GlaxoSmithKline boss Emma Walmsley said she was “extremely […]
It looks like GlaxoSmithKline’s concerns about its respiratory syncytial virus (RSV) vaccine in pregnant women aren’t going to be resolved quickly. After suspending three trials […]
Sanofi and GlaxoSmithKline weathered clinical trial delays for their Covid-19 vaccine, but the partners now have data to support filings seeking regulatory authorizations. Key features […]
GlaxoSmithKline’s consumer health business will be named Haleon following its planned spinoff and listing on the London Stock Exchange later this year, according to the […]
Products such as Voltaren, Sensodyne and Panadol to regroup under new stock market listing in summer GSK has revealed that its consumer healthcare business, whose […]
GlaxoSmithKline has a lot riding on its respiratory syncytial virus (RSV) vaccine, which it thinks could be a $4 billion product at peak, so investors […]
lupusAstraZeneca’s Saphnelo has become the first new drug to be approved to treat the autoimmune disease systemic lupus erythematosus (SLE) in the EU for more […]
Seattle, US vaccine startup Curevo has raised $60 million in first-round financing that it says will be used to run head-to-head trials of its experimental […]
Eli Lilly has been granted an emergency use authorisation from the FDA for bebtelovimab, its second COVID-19 antibody drug and a rival to GlaxoSmithKline and […]
Riot in ranks sends ‘strong message’ against tilt at GlaxoSmithKline’s consumer division Unilever’s plan A was to make a huge acquisition; plan B is not […]
The ‘step-change’ in growth for the core pharma division has barely started, but the CEO is secure for now Emma Walmsley is at the starting […]
GlaxoSmithKline’s COVID-19 products – antibody drug Xevudy and a vaccine adjuvant – helped drive a 5% increase in 2021 revenues to £34 billion ($46 billion), […]
Pharmaceutical company’s boss, Emma Walmsley promised a ‘step-change in growth’ after better than expected results GSK made £1.4bn from Covid-related medicines last year, beating earnings […]
The former GSK executive has found her niche at ViiV Healthcare developing HIV drugs, and is optimistic a cure will be found A lot has […]
A patent dispute between ViiV Healthcare and Gilead Sciences has been resolved, with Gilead agreeing to pay a $1.25 billion settlement as well as royalties […]
The first patient has been treated with an implantable bioelectronic device developed by Galvani Therapeutics, set up by GlaxoSmithKline and Alphabet’s Verily Life Sciences in […]
Delivering a minor heart attack to the share price, however temporarily, is not a good look It was fun while it lasted. Unilever says it […]
Company says data shared by GSK suggests ‘fundamental value’ of business no higher than offer Unilever has said it will not increase its offer for […]
Hal Barron to leave just as pressure builds on GSK to come up with new medicines Pharmaceuticals company GSK’s chief scientific officer is jumping ship, […]
Deal could swell Unilever’s debt pile says ratings agency Fitch Unilever has been warned that buying GlaxoSmithKline’s consumer products arm is likely to substantially swell […]
This could be a long campaign and, despite all the difficulties, there is a logic to the proposal Even a Marmite reaction – some loving […]
A World Health Organization (WHO) panel has given the green light to two new drugs to treat COVID-19. US-based Eli Lilly’s baricitinib (Olumiant), a Janus […]
GlaxoSmithKline (GSK) claims it has rejected three unsolicited, conditional and non-binding proposals from Unilever to acquire GSK Consumer Healthcare in a deal worth approximately $68.4 […]
Dove soap maker’s shares are biggest faller on FTSE 100 after offer for consumer products arm is rebuffed Unilever has pledged to grow its health, […]
Unilever’s offer represents only a modest premium to its current value, according to some leading analysts Unilever’s rebuffed £50bn takeover offer for GSK’s consumer healthcare […]
Analysis: drugmaker appears to be holding out for what would be one of largest ever deals in London after rejecting Unilever bids With typical bravado, […]
GlaxoSmithKline places shingles vaccine Shingrix is among its top prospects, with peak sales potential of almost $6 billion. Now, Pfizer and BioNTech are joining forces […]
GlaxoSmithKline’ majority-owned HIV unit ViiV has scored a key FDA approval, getting approval for its long-acting drug cabotegravir as the first injectable for pre-exposure prophylaxis […]
Glaxo’s consumer healthcare business is to demerge from wider group from mid-2022 The pharmaceutical firm GlaxoSmithKline has hired the former Tesco boss Sir Dave Lewis […]
Johnson & Johnson’s also-ran COVID-19 vaccine has been cleared in the EU as a booster shot, although its role in the US could be impacted […]
Early trials show jab effective in people of all ages who have already received doses of any vaccine Coronavirus – latest updates See all our […]
The UK medicines regulator has approved GlaxoSmithKline and Vir Biotech’s antibody for COVID-19, Xevudy, which has been shown to be effective against the new Omicron […]
GlaxoSmithKline has formed a five-year partnership with Oxford University to set up a new institute that will apply machine learning and functional genomics to the […]
GlaxoSmithKline has found a replacement for head of vaccines R&D Emmanuel Hanon, who left the company for a US biotech earlier this year, hiring Phil […]
GlaxoSmithKline has joined the ranks of drugmakers trying to develop new drugs for non-alcoholic steatohepatitis (NASH) – a condition with no approved therapies and a […]
GlaxoSmithKline sees enough promise in the early clinical data of a novel NASH drug to pay its developer, Arrowhead Pharmaceuticals, $120 million up front for […]
People living with HIV in England and Wales now have an alternative to daily oral tablets, after NICE backed NHS use of two long-acting injectable […]
The US has made a sizeable order for GlaxoSmithKline and Vir Biotechnology’s antibody-based COVID-19 treatment sotrovimab said to be worth approximately $1 billion. The deal […]
Routine vaccination with human papillomavirus vaccines have resulted in an 87% reduction in cervical cancer cases in England, and could even see the need for […]
GlaxoSmithKline said today it would halt further development of its antibody for severe COVID-19 pneumonia – otilimab – in order to focus its resources on […]
With just a few years to turn the group around, the boss could do without a bellicose hedge fund breathing down her neck Few companies […]
Hedge fund Bluebell also demands replacement of GlaxoSmithKline chairman Sir Jonathan Symonds The British drugmaker GlaxoSmithKline has come under fresh pressure to sell off its […]
The WHO has given a green light to widespread use of GlaxoSmithKline’s malaria vaccine in Africa, in what could be a major turning point in […]
World Health Organization’s director general hails ‘historic day’ in fight against parasitic disease The World Health Organization has recommended the widespread rollout of the first […]
GlaxoSmithKline has ended its collaboration with Germany’s Merck KGaA’s cancer treatment bintrafusp alfa, after a trio of failed clinical trials. Given the disappointments the decision […]
Sanofi has said that it won’t develop its mRNA-based vaccine for COVID-19 any further, even though it seemed to work in an early-stage trial, and […]
Life sciences companies are using “digital twins” for everything from drug discovery to manufacturing. A panel of experts at MedCity News’ INVEST Digital Health conference […]
Activist hedge fund Bluebell Capital Partners has joined Elliott Investment in taking a stake in GlaxoSmithKline and pushing for change at the drugmaker. In a […]
Bluebell Capital takes stake in pharma giant and puts pressure on Emma Walmsley GSK’s chief executive, Emma Walmsley, has come under pressure from a second […]
Artificial intelligence will be used to develop personalised treatments while investigating role of genetics The pharmaceuticals firm GSK has struck a five-year partnership with King’s […]
Pfizer has vaulted ahead with its respiratory syncytial virus (RSV) vaccine, closing the gap with GlaxoSmithKline and Johnson & Johnson as the companies strive to […]
Vague demand for board refresh from Causeway likely a hangover from £2bn rights issue The last time Rolls-Royce had an US activist fund on its […]
As a top vaccine maker, GlaxoSmithKline has been a laggard in the COVID-19 vaccine race, but has put on a late burst of speed with […]
GlaxoSmithKline’s big gamble on Merck KGaA’s bintrafusp alfa has gone from bad to worse, after the drug failed yet another mid-stage trial. The latest disappointment […]
The EU regulator has approved FibroGen and Astellas Evrenzo for adults with anaemia caused by chronic kidney disease (CKD), just days after the FDA turned […]
GlaxoSmithKline drug Jemperli is now FDA approved for treating solid tumors throughout the body as long as they have a particular genetic signature. Expanding the […]
The FDA has approved GlaxoSmithKline’s latecomer PD-1 inhibitor Jemperli for a second use that will significantly extend the patient population eligible for treatment with the […]
Pfizer and BioNTech have formally asked for FDA approval of a third dose of their COVID-19 vaccine BNT162b2 in people aged over 16, as the […]
The FDA has demanded another clinical trial of FibroGen and AstraZeneca’s roxadustat for anaemia caused by chronic kidney disease (CKD) before it will consider approval, […]
GlaxoSmithKline has said that Brian McNamara – currently head of its three-year-old consumer health joint venture with Pfizer – will retain the top job at […]
The EMA has kicked off a rolling review of a COVID-19 vaccine from Sanofi and GlaxoSmithKline, which started a 35,000-patient phase 3 trial in May. […]
GlaxoSmithKline wants to sell more than a third of the space at its R&D campus in Stevenage, UK, to a new bioscience cluster that it […]
Pharmaceuticals firm thinks creating cluster of companies at its site could result in up to 5,000 jobs GlaxoSmithKline is seeking to create a £400m campus […]
Safety concerns seem to have scuppered any hope of a near-term approval for FibroGen and AstraZeneca’s roxadustat for anaemia associated with chronic kidney disease (CKD) […]
GlaxoSmithKline’s head of oncology Axel Hoos has resigned from the company, and will take up a new role as chief executive of US biotech Scorpion […]
GlaxoSmithKline is paying Alector $700 million up front to share in the development of the biotech’s two lead drugs, which offer potentially broad application in […]
GlaxoSmithKline’s board had responded to the broadside attack delivered by activist investor Elliott Management yesterday, saying it stands firmly behind the leadership of chief executive […]
Hedge fund had sought to force Emma Walmsley to reapply for her job ahead of drugmaker’s corporate split The drugmaker GlaxoSmithKline has issued a firm […]
The first stage of the Nissan project in Sunderland will deliver 9GWh of capacity but there is a very long way to go in this […]
US hedge fund ratchets up pressure on Dame Emma Walmsley before company’s demerger next year The US activist investor Elliott Management has in effect demanded […]
GlaxoSmithKline chief executive Emma Walmsley was no doubt hoping that an upbeat assessment of the firm’s prospects at an investor meeting last week would deflect […]
GlaxoSmithKline chief executive Emma Walmsley was no doubt hoping that an upbeat assessment of the firm’s prospects at an investor meeting last week would deflect […]
Emma Walmsley still has time to build belief in product pipeline – but clinging onto consumer division hardly shouts confidence “I am a change agent,” […]
Firm aims to boost pharmaceutical and vaccine business by 5% annually for five years GSK has cut its dividend and set ambitious sales targets as […]
The boss’s plan to divide the pharma giant has support – but her own position may hinge on a crucial presentation this week Dame Emma […]
GlaxoSmithKline is paying iTeos Therapeutics $625 million up front to share in the development of an antibody that targets the TIGIT protein, a hot target […]
Giving landlords and tenants six months to work out a deal on arrears could stop an wave of bankruptcies in the sector If it really […]
GlaxoSmithKline has staked a claim to the fast-moving category of cancer therapies targeting the TIGIT immune checkpoint, agreeing a $2 billion plus licensing agreement with […]
FDA authorization of the Covid-19 antibody drug from Vir Biotechnology and GlaxoSmithKline adds a third antibody drug for treating early cases of the disease that […]
GlaxoSmithKline’s COVID-19 drive has advanced on two fronts, with the start of phase 3 trials of its Sanofi-partnered vaccine candidate as well as an FDA […]
GlaxoSmithKline has sold its entire stake in its respiratory partner Innoviva, raising $392 million and simplifying its business ahead of a split into two. GSK […]
Announcement follows encouraging news from collaboration with French drugmaker Sanofi Coronavirus – latest updates See all our coronavirus coverage GlaxoSmithKline has unveiled positive interim results […]
Speculation is mounting GlaxoSmithKline’s CEO Emma Walmsley may pay the price for the company’s lacklustre performance, after the dreaded activist investor Elliott Management built a […]
Canadian biotech Medicago has the data it was hoping for from a phase 2 trial of its COVID-19 vaccine, partnered with GlaxoSmithKline, and is now […]
Whatever Elliott Management’s intentions, the UK-based pharmaceutical firm will now be seen as a national asset GlaxoSmithKline’s progress on Covid vaccines has been slow, frustrating […]
Sanofi and GlaxoSmithKline reported positive preliminary Phase 2 data for their Covid-19 vaccine. Though several vaccines have been authorized, the companies say that their vaccine’s […]
Sanofi and GlaxoSmithKline seem to be getting somewhere with their COVID-19 vaccine at last, announcing plans to move to phase 3 following supportive mid-stage trial […]
News will offer some some relief for GSK chief Emma Walmsley, who has been under pressure from investor GlaxoSmithKline is in the running to bring […]
The EMA has begun a rolling review of a COVID-19 antibody developed by GlaxoSmithKline and Vir BioTech which could become the fourth drug of its […]
Health commissioner says plan is to reduce hospitalisation and tackle long-term impact of Covid Coronavirus – latest updates See all our coronavirus coverage Three Covid […]
GlaxoSmithKline’s CEO Emma Walmsley said the company is focused on pursuing its strategy to spin off its consumer business after downbeat set of first quarter […]
The CEO’s best policy is to ignore the noise. The decluttering demerger plan looks solid and is backed by shareholders It was not a knockout […]
CEO is under pressure to improve GSK’s performance after profit slump and arrival of activist shareholder GlaxoSmithKline’s chief executive, Emma Walmsley, has vowed to lead […]
This week’s lacklustre results will strengthen boss Emma Walmsley’s case for reform – but also inspire her critics When the American hedge fund Elliott Management […]
The FDA has approved GlaxoSmithKline’s Jemperli (dostarlimab) immunotherapy, a drug acquired through its $5.1 billion acquisition of Tesaro, for certain patients with endometrial cancer. With […]
The FDA approved GlaxoSmithKlie drug dostarlimab (Jemperli) for endometrial cancer that carries a particular genetic signature. The immunotherapy now joins Merck’s Keytruda as the checkpoint […]
The EMA has started reviewing the emergency use application for GlaxoSmithKline and Vir Biotech’s COVID-19 antibody VIR-7831, which could become the fourth drug of its […]
Activist investor Elliott Management has built a significant stake in GlaxoSmithKline, after a poor run of clinical trial results this year raised questions about management’s […]
UK pharmaceutical company has been under pressure to rebuild portfolio of new medicines Shares in GlaxoSmithKline jumped on Thursday, after it emerged that the activist […]
AstraZeneca’s Lynparza (olaparib) blazed a trail for the new class of PARP drugs when it was approved in 2014 to treat ovarian cancer. The drug […]
Antios has raised $96 million in Series B financing to support the ongoing phase 2 development of its hepatitis B drug candidate, ATI-2173. There are […]
Despite having the global pandemic, the biopharma companies were involved in multiple M&A, licensing deals. The major focus of the year remains the production and […]
More than 20 world leaders have called for an international treaty for pandemic preparedness to protect the world from future health crises. Backed by the […]
Two antibodies targeting different parts of the COVID-19 virus spike protein, from Eli Lilly and GlaxoSmithKline/Vir Biotech, can cut viral load dramatically within a week. […]
Deal is intended to boost domestic supply amid fears potential export bans could hit vaccine shipments Coronavirus – latest updates See all our coronavirus coverage […]
GlaxoSmithKline has fired its former research boss Moncef Slaoui from the board of Galvani Bioelectronics, a company it majority owns, after an internal investigation found […]
Drugmaker dismisses former research boss from role at Galvani Bioelectronics GSK has dismissed its former research boss Moncef Slaoui, who became US national vaccine chief […]
GSK has terminated Moncef Slaoui as board chair of Galvani Bioelectronics after an investigation substantiated a sexual harassment claim dating to his tenure at the […]
The UK’s chief scientific adviser loves good food, enjoys a Scandi drama – and has been called ‘the richest civil servant in history’ Sir Patrick […]
The UK’s chief scientific adviser loves good food, enjoys a Scandi drama – and has been called ‘the richest civil servant in history’ Sir Patrick […]
The positive data for the antibody drug from Vir Biotechnology and GlaxoSmithKline give a clearer picture of how and when these treatments could help. Last […]
European regulators have refused to back GlaxoSmithKline’s daily triple therapy Trelegy Ellipta for asthma, denying a label extension because there was no evidence to show […]
Though GlaxoSmithKline’s drug otilimab missed the main goal of a mid-stage Covid-19 study, the company points to better data in a subgroup of older patients. […]
Sanofi and GlaxoSmithKline are restarting clinical development of their COVID-19 vaccine, which was delayed after hitting a snag late last year. In December interim phase […]
Technology that speeded the development of Covid vaccines has potential to transform the pharmaceutical industry The hunt for new medicines has often been more like […]
GlaxoSmithKline is expanding a coronavirus antibody collaboration with US biotech Vir, to include potential therapies for flu and other respiratory viruses. The big UK pharma […]
The amended pact follows a collaboration begun last year when GlaxoSmithKline paid Vir Biotechnology $250 million to team up on potential treatments for Covid-19. The […]
Novartis exited novel antibiotics R&D three years ago, but is clearly still interested in the category – its Sandoz unit has just spent $350 million […]
The European Commission has given a green light to the use of ViiV Healthcare’s Rukobia as a treatment for people with HIV that has developed […]
The Anglo-Swedish firm already had a strong lineup of cancer drugs when vaccine success gave it a further boost Before the pandemic, AstraZeneca was highly […]
The Amazon founder gains time for other projects, such as space and newspapers, while still making the big decisions Jeff Bezos is stepping aside at […]
GlaxoSmithKline and CureVac are to begin developing a next generation vaccine targeting emerging variants of the coronavirus – although it is unlikely to be ready […]
Companies hope to have next generation of vaccines against emerging variants by next year GlaxoSmithKline and Germany’s CureVac have reached a €150m (£132m) agreement to […]
Novartis’ multiple sclerosis drug has been given the green light by the European Medicines Agency’s CHMP scientific committee, paving the way for a likely approval […]
GlaxoSmithKline has suffered another research setback after it axed a phase 2 trial of an anti-LAG3 drug in patients with ulcerative colitis, following a major […]
GlaxoSmithKline’s big gamble on a cancer drug developed by Germany’s Merck KGaA looks unlikely to pay out, after bintrafusp alfa failed to outperform US-based Merck […]
Women with newly-diagnosed advanced ovarian cancer have a new treatment option in England after NICE recommend interim funding for GlaxoSmithKline’s Zejula (niraparib) in final guidance. […]
ViiV’s Tivicay is to become available in Europe in a new dispersible tablet form to treat children living with HIV. The joint venture, majority-owned by […]
The dire state of UK manufacturing has left us dependent on other nations. We may soon find out why some call this a ‘national security […]
GlaxoSmithKline has closed the year with a flurry of deals, leaving its development pipeline bulging like Santa’s sack as chief scientific officer Hal Barron pursues […]
GlaxoSmithKline’s Benlysta has been on the market for almost a decade, but it still has some tricks up its sleeve – it’s just become the […]
Trials reveal vaccine failed to produce a strong immune response in older people Coronavirus – latest updates See all our coronavirus coverage A coronavirus vaccine […]
Sanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) mainly to itself since June 2019, […]
Trans-Atlantic biotech venture capital firm SR One has completed its spin-out from GlaxoSmithKline and closed its first fund with $500m in its coffers. The VC […]
GlaxoSmithKline saw a recovery in its vaccine sales in the third quarter after a big hit in the second as a result of the COVID-19 […]
Eli Lilly has asked the FDA for an Emergency Use Authorization for its COVID-19 antibody therapy, after announcing new efficacy data from an ongoing trial. […]
GlaxoSmithKline and partner Vir Biotechnology are to expand a trial of an experimental antibody to treat COVID-19, putting heat on Regeneron’s rival that has been […]
Drugs company says infection controls at some of its sites are so secure the app is not needed Coronavirus – latest updates See all our […]
World’s largest vaccine makers to begin testing on people in US with eye on rollout in early 2021 Coronavirus – latest updates See all our […]
An antisense drug developed by GlaxoSmithKline has been shown to suppress the hepatitis B virus (HBV) in a phase 2 trial, raising hopes of a […]
GlaxoSmithKline has approval on both sides of the Atlantic for its multiple myeloma drug Blenrep, after getting the nod from the European Commission. Blenrep (belantamab […]
Blenrep, an antibody-drug conjugate, is the first drug approved for multiple myeloma that targets the antigen BCMA. Several other companies are also developing BCMA-targeting therapies […]
The US government has selected a potential vaccine from Sanofi and GlaxoSmithKline for its Operation Warp Speed COVID-19 vaccine development initiative, committing up to $2.1 […]
The companies will provide 100 million doses of their jointly developed vaccine. But with a Phase I/II study planned in September, it is behind in […]
Companies can return to work from 1 August, but many employers are making their own plans Companies ready to defy Boris Johnson’s planned return to […]
AstraZeneca has beaten analysts’ expectations in its second quarter results, outshining its UK counterpart GlaxoSmithKline, which has been hit by disruption caused by the COVID-19 […]
The UK government has signed its fourth coronavirus vaccine deal, snapping up 60 million doses of an experimental shot being developed by Sanofi and GlaxoSmithKline. […]
GlaxoSmithKline and Sanofi Pasteur could supply vaccine by early next year if it is successful Coronavirus – latest updates See all our coronavirus coverage The […]
GlaxoSmithKline is closing in on EU approval for its first-in-class BCMA-targeting drug Blenrep, after getting a green light from the EMA’s human medicines committee. Blenrep, […]
AstraZeneca and GSK both release results this week. But picking winners in the sector may be complicated It was the press announcement heard around the […]
AstraZeneca’s triple therapy for chronic obstructive pulmonary disease (COPD), Breztri Aerosphere (budesonide+glycopyrrolate+formoterol fumarate), has been approved in the US following a rejection last year. Approval […]
GSK’s share price has been left standing by AstraZeneca’s high-risk success in cancer treatments Monday’s most important vaccine news was the promising early data from […]
Stake of 10% in CureVac is part of deal that could eventually be worth more than £800m Coronavirus – latest updates See all our coronavirus […]
The UK has secured 90 million doses of two different COVID-19 vaccines from BioNTech/Pfizer and Valneva, with an option of 40 million doses if they check out in trials. There […]
The Oncologic Drugs Advisory Committee voted 12-0 that the benefit-risk profile of belantamab mafodotin supported the drug. The vote came despite concerns expressed by the […]
The FDA’s Oncologic Drugs Advisory Committee will convene Tuesday to discuss the drug, belantamab mafodotin. Despite the drug’s first-in-class potential, the briefing document for the […]
The company said Tuesday that a final analysis of its Phase IIb/III study of cabotegravir showed greater efficacy in HIV prevention than Gilead’s Truvada. The […]
Copyright © 2024 | WordPress Theme by MH Themes